ResMed Inc. (NYSE:RMD) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.48% to 61.73 with around 58151 shares have changed hands in this session. ResMed (RMD) revealed that industry leader Carlos M. Nunez, MD, will become ResMed’s chief medical officer, effective January 3, 2017.
Nunez most recently served as senior vice president of medical affairs for Becton, Dickinson and Company. He will be based in ResMed’s San Diego headquarters and will report directly to CEO Mick Farrell and President/COO Rob Douglas.”I’m delighted to welcome Carlos Nunez to ResMed,” said Farrell.
“Carlos has great depth in clinical and medical technology, and great breadth in healthcare informatics and business management. His proven leadership capabilities and track record of collaboration across global teams make him an ideal addition to our executive team. Carlos will play a key role in accelerating ResMed’s 2020 growth strategy, including clinical trials of sleep apnea, neuromuscular disease and COPD, as well as in connected care.” The stock is going forward its fifty-two week low with 24.15% and lagging behind from its 52-week high price with -12.02%.
Similar, the positive performance for the quarter recorded as -2.22% and for the year was 19.71%, while the YTD performance remained at 17.97%. RMD has Average True Range for 14 days of 1.21.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -4.13% to close at $18.32. Juno Therapeutics, Inc. (JUNO) along with Celgene Corp. (CELG) reported that FDA has granted Breakthrough Therapy designation to investigational drug JCAR017 for the treatment of patients with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma. This will include diffuse large B-cell lymphoma, not otherwise specified, Primary Mediastinal B-cell Lymphoma or Grade 3B Follicular Lymphoma.
The companies noted that the European Medicines Agency Committee for Medicinal Products for Human Use and Committee for Advanced Therapies have granted JCAR017 access to the Priority Medicines scheme for relapsed/refractory diffuse large B-cell lymphoma or DLBCL.
Mark Gilbert, Juno’s Chief Medical Officer said, “The Breakthrough Therapy designation from the FDA and PRIME eligibility from EMA for JCAR017 highlight the need for new treatment options for patients with DLBCL, particularly for the important number of patients who do not respond to initial therapy or with relapsed disease.” Moving forward to saw long-term intention, the experts calculate Return on Investment of -20.30%. The stock is going forward its fifty-two week low with 4.27% and lagging behind from its 52-week high price with -63.15%. JUNO last month stock price volatility remained 5.98%.